On average, about 10% of women diagnosed with breast cancer have an inherited predisposition toward the disease. One of the most important indicators of this hereditary predisposition toward breast and ovarian cancer is a familial history of malignancies, and therefore, the initial stage in this clarification process is the construction of a family tree encompassing information about cancers among relatives. Based on the relevant family history of breast and ovarian cancer, a family practitioner will know whether additional genetic counselling is necessary.
Numerous breast and ovarian cancer patients are unaware of the consequences and the importance of genetic testing as a preventive care function intended for their protection as well as that of their daughters and female relatives, and as a result, they refrain from seeking genetic counseling and avoid screening tests.
The Interactive Family History Questionnaire is designed to help you clarify whether there is a genetic predisposition toward breast and ovarian cancer in your family.
Please click here to complete the interactive questionnaire (in Hebrew).
The content that appears in the questionnaire was intended for informational purposes only, and does not constitute medical advice or a professional opinion. Nor is it intended to replace consultation with an expert in any field. Please review the terms of use of the questionnaire (in Hebrew).
For additional information about the program and hereditary breast and ovarian cancer:
Hebrew: Prevention GENEration - the importance of genetic counselling for hereditary breast and ovarian cancer (in Hebrew). Prevention GENEration brochure (in English). Prevention GENEration brochure (in Russian).
Forum for Genetic Carriers and Women at High Risk of Developing Breast and Ovarian Cancer (in Hebrew). Extensive information on genetics and cancer (in Hebrew). Standard criteria for referral for genetic counselling (in Hebrew). Click here to view greetings delivered by Mrs. Rosa Dembitzer, the driving force behind the inception of the "Prevention GENEration" program.
For further information about the program, please contact the Program Coordinator at:
E-Mail: prev-gene@szmc.org.il Tel.: +972-2-564.52.17.
Our thanks go to Professor Ephrat Levy-Lahad, Head of the Department of Genetics at Shaare Zedek Medical Center, for her assistance in developing this questionnaire.